Projekt · Dnr 2017-00250 · Källa: Vinnova

Improved, affordable single strain whole cell-B subunit oral cholera vaccine

Koordinator
Göteborgs universitet, Avdelningen mikrobiologi och immunologi
Projekttid
2017-06-01 till 2020-10-31 (avslutat)
Beviljat bidrag
5 950 000 SEK
Diarienummer
2017-00250

Beskrivning

The goal has been to develop an improved, thermostable and affordable enterocoated capsule oral cholera vaccine (OCV), "Hillchol-B", based on lyophilized formalin-inactivated serotype Hikojima bacteria and recombinantly produced cholera toxin B subunit (rCTB). This has been accomplished at lab scale and a program launched for the further industrial development and clinical testing towards international licensing and WHO prequalification. The properties of Hillchol-B should make it highly attractive for use in the control of both epidemic and endemic cholera world-wide. We have successfully developed at laboratory scale an improved, thermostable and affordable enterocoated capsule oral cholera vaccine (OCV), "Hillchol-B", based on lyophilized formalin-inactivated serotype Hikojima bacteria and recombinantly produced cholera toxin B subunit (rCTB). A program is launched for the further industrial development and clinical testing towards international licensing and WHO prequalification of the novel vaccine. Its properties should make Hillchol-B highly attractive for use in the control of both epidemic and endemic cholera world-wide.

Öppna hos Vinnova

Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.

Liknande

  1. HIV peptides linked to cholera toxin B subunit, E! 3421 HIVVAC

    CRUCELL SWEDEN AB · 2004-07-01 · 3 000 000 SEK · Projekt

  2. E!11019, OptiFemVac, Abera Bioscience AB

    Abera Bioscience AB · 2017-04-01 · 2 351 980 SEK · Projekt

    The purpose was to engineer bacterial outer membrane vesicles (OMVs) into a versatile and modular platform for recombinant vaccine development. Technology was developped to couple high amounts of antigenic proteins to OMV particles and vaccine candidates against either Zika virus or Humano papiloma …

  3. Nytt vaccin mot mastit hos nötkreatur orsakad av Staphylococcus aureus

    Intervacc AB · 2020-05-01 · 1 943 296 SEK · Projekt

    Mastitis is one of the most important diseases in dairy cattle causing significant losses to the dairy industry. Staphylococcus aureus is the causative agent of around 25% of contagious mastitis cases in Europe, accounting for over 2.6 million cases at an annual cost of 597M€. This project aimed to …

  4. OJ/2023/DPR/26575 - External quality assessment of antimicrobial susceptibility testing for Salmonella and Campylobacter - Lot 1: AST EQA for Salmonella enterica - Lot 2: AST EQA for Campylobacter spp.

    European Centre for Disease Prevention and Control · 2024-01-19 · sista anbudsdag 2024-02-29 · 695 000 EUR · Upphandling

    Lot 1 covers the organisation of an EQA exercise for phenotypic and genotypic antimicrobial susceptibility testing including detection and confirmation of ESBL-, acquired AmpC, and carbapenemase-producing Salmonella enterica Lot 2 covers the organisation of an EQA exercise for species identification…

  5. Plate based single cell kits

    Kungliga Tekniska högskolan · 2025-05-16 · sista anbudsdag 2025-06-25 · 20 000 000 SEK · Upphandling

    The aim and purpose of the procurement is to be able to acquire reagents for high throughput plate based single cell transcriptomic and/or chromatin accessibility experiments that rely on the split-and pool principles. For split-and-pool, several cells are initially pooled together in one well, rece…